Cargando…
Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hos...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963397/ https://www.ncbi.nlm.nih.gov/pubmed/35351942 http://dx.doi.org/10.1038/s41598-022-09170-4 |
_version_ | 1784677981445160960 |
---|---|
author | Miyazaki, Kazuhito Yoshimura, Yukihiro Miyata, Nobuyuki Sasaki, Hiroaki Shiba, Aya Aga, Masaharu Hamakawa, Yusuke Taniguchi, Yuri Misumi, Yuki Agemi, Yoko Shimokawa, Tsuneo Okamoto, Hiroaki Tachikawa, Natsuo |
author_facet | Miyazaki, Kazuhito Yoshimura, Yukihiro Miyata, Nobuyuki Sasaki, Hiroaki Shiba, Aya Aga, Masaharu Hamakawa, Yusuke Taniguchi, Yuri Misumi, Yuki Agemi, Yoko Shimokawa, Tsuneo Okamoto, Hiroaki Tachikawa, Natsuo |
author_sort | Miyazaki, Kazuhito |
collection | PubMed |
description | Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir. |
format | Online Article Text |
id | pubmed-8963397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89633972022-03-30 Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study Miyazaki, Kazuhito Yoshimura, Yukihiro Miyata, Nobuyuki Sasaki, Hiroaki Shiba, Aya Aga, Masaharu Hamakawa, Yusuke Taniguchi, Yuri Misumi, Yuki Agemi, Yoko Shimokawa, Tsuneo Okamoto, Hiroaki Tachikawa, Natsuo Sci Rep Article Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir. Nature Publishing Group UK 2022-03-29 /pmc/articles/PMC8963397/ /pubmed/35351942 http://dx.doi.org/10.1038/s41598-022-09170-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Miyazaki, Kazuhito Yoshimura, Yukihiro Miyata, Nobuyuki Sasaki, Hiroaki Shiba, Aya Aga, Masaharu Hamakawa, Yusuke Taniguchi, Yuri Misumi, Yuki Agemi, Yoko Shimokawa, Tsuneo Okamoto, Hiroaki Tachikawa, Natsuo Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title | Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title_full | Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title_fullStr | Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title_full_unstemmed | Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title_short | Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study |
title_sort | acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in covid-19 patients: an observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963397/ https://www.ncbi.nlm.nih.gov/pubmed/35351942 http://dx.doi.org/10.1038/s41598-022-09170-4 |
work_keys_str_mv | AT miyazakikazuhito acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT yoshimurayukihiro acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT miyatanobuyuki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT sasakihiroaki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT shibaaya acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT agamasaharu acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT hamakawayusuke acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT taniguchiyuri acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT misumiyuki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT agemiyoko acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT shimokawatsuneo acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT okamotohiroaki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy AT tachikawanatsuo acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy |